<DOC>
	<DOCNO>NCT02617615</DOCNO>
	<brief_summary>A Phase 1 , First-in-Human , Randomized , Placebo-Controlled , Double-Blind Study Evaluate Safety , Tolerability , Pharmacokinetic Profiles Single Ascending Multiple Oral Doses MB-110 Healthy Volunteers Evaluate Antiviral Activity MB-110 Hepatitis C Virus Infected Subjects</brief_summary>
	<brief_title>A Trial Evaluate Safety , Tolerability , PK Antiviral Activity MB-110 Hepatitis C Virus Infected Patients</brief_title>
	<detailed_description>The present study divide 2 part . Part A randomized , double blind , placebo control , sequential ascend single multiple oral dos design evaluate safety , tolerability , PK , food effect MB-110 healthy volunteers.Part A recruit 2 group ( Groups 1 2 ) 8 healthy volunteer group . Within group , 8 subject randomize 6:2 receive MB-110 versus placebo.Subjects Group 1 receive either 50 mg MB-110 placebo fast condition first visit ( Cohort 1 ) ; either 50 mg MB-110 placebo feed condition second visit ( Cohort 3 ) food effect evaluate . Subjects Group 2 receive either 100 mg MB-110 placebo fast condition first visit ( Cohort 2 ) ; 200 mg MB-110 placebo fast condition second visit ( Cohort 4 ) . In Cohort 5 , 8 subject select Group 1 , Group 2 , new recruitment washout time insufficient previous cohort . Subjects Cohort 5 randomize 6:2 receive MB-110 dose 200 mg placebo daily 5 consecutive day . Part B randomize , double-blind , placebo-controlled , multiple ascend oral dose design evaluate safety , tolerability , PK , antiviral activity MB-110 subject infect Hepatitis C virus genotype 1b , 2a , 3a.Part B recruit 3 cohort ( Cohorts 6 , 7 , 8 ) treatment-naïve HCV infect subject cohort . In Cohort 6 , 12 subject infect Hepatitis C virus genotype 1b randomize 5:5:2 receive two dose level MB-110 placebo daily 3 consecutive day . In Cohort 7 , 6 subject infect Hepatitis C virus genotype 2a randomize 5:1 receive MB-110 placebo daily 3 consecutive day . In Cohort 8 , 6 subject infect Hepatitis C virus genotype 3a randomize 5:1 receive MB-110 placebo daily 3 consecutive day .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Part A : To eligible participate study , subject must meet follow criterion screen : 1 . Male female 20 55 year age inclusive 2 . For female , breastfeeding , pregnant , postmenopausal least 2 year , surgically sterile , willing use double barrier method [ intrauterine device ( IUD ) plus condom , spermicidal gel plus condom ] contraception , effective contraceptive method screen 30 day last dose study drug 3 . For male , willing use reliable form contraception ( use male condom spermicide partner fulfil criterion ) , abstinence screen 30 day last dose study drug 4 . Body weight ≥ 50 kg inclusive body mass index ( BMI ) range 19.0 30.0 kg/m2 , extremes include 5 . Good physical mental health condition basis medical history vital sign perform screen 6 . Healthy basis clinical laboratory test perform screen . If result outside normal reference range , subject may include investigator judge abnormalities deviation normal clinically significant . This determination must record subject 's source document initial investigator . This applicable laboratory abnormality list exclusion criterion [ use Division Microbiology Infectious Diseases ( DMID ) Adult Toxicity criteriasee Section 13.3 ] . 7 . Nonsmoking least 3 month prior screen , confirm urine cotinine dipstick test 8 . 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function : Heart rate ( HR ) 50 100 bpm QTcF interval ≤ 430 m ( male ) ≤ 450 m ( female ) QRS interval low 120 m PR interval ≤ 200 m Willing abstain caffeine xanthinecontaining beverage food , include coffee tea , alcohol , grapefruit juice , bitter orange study period 10 . Willing sign Informed Consent Form ( ICF ) indicate understands purpose procedure require study willing participate study Exclusion Criteria Part A : Subjects must exclude meet follow criterion : 1 . Breastfeeding pregnant female 2 . History heart arrhythmia ( clinically relevant ) baseline prolongation QTcF interval &gt; 430 m ( male ) &gt; 450 m ( female ) , history risk factor Torsade de Pointes syndrome ( hypokalemia , family history long QT syndrome ) , HR ( supine pulse obtain vital sign ) &lt; 50 bpm &gt; 100 bpm 3 . History suspicion current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance study procedures 4 . Hepatitis A , B , C infection ( confirm hepatitis A antibody IgM , hepatitis B surface antigen , hepatitis C virus antibody , respectively ) HIV1 HIV2 infection ( confirm CLIA test ) study screen 5 . Clinically relevant , currently active underlie gastrointestinal , cardiovascular , nervous system , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease 6 . History drug allergy , limited , sulfonamides penicillin , drug allergy witness previous trial investigational drug 7 . Any condition , opinion investigator , would compromise study wellbeing subject prevent subject meeting performing study requirement 8 . Use concomitant medication , include overthecounter product , herbal medication dietary supplement period 14 day study 9 . Donation blood plasma 250 mL within 60 day precede study 10 . Subjects one follow laboratory abnormality screen define DMID Adult Toxicity Table : Hemoglobin grade 1 great ( ≤ 10.5 gm/dL ) Platelet count grade 1 great ( &lt; 100,000/mm3 ) Absolute neutrophil count grade 1 great ( ≤ 1500/mm3 ) Aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) grade 1 great ( &gt; 1.1x ULN [ upper limit range ] ) Total bilirubin grade 1 great ( &gt; 1.1x ULN ) Lipase grade 1 great ( &gt; 1.1x ULN ) Serum creatinine grade 1 great ( &gt; 1.1x ULN ) Any laboratory abnormality ≥ grade 1 [ Note : Retesting abnormal lab value may lead exclusion allow ( without prior Sponsor approval ) . Retesting take place unscheduled visit Screening phase ( admission/baseline ) ] 11 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment psychiatric illness , history suicide attempt depression 12 . Acute illness within 2 week prior dose , unless approve Sponsor 's Medical Monitor Inclusion Criteria Part B : To eligible participate study , subject must meet following criterion : 1 . Male female 20 65 year age inclusive 2 . For female , breastfeeding , pregnant , postmenopausal least 2 year , surgically sterile , willing use double barrier method [ intrauterine device ( IUD ) plus condom , spermicidal gel plus condom ] contraception , effective contraceptive method screen 30 day last dose study drug 3 . For male , willing use reliable form contraception ( use male condom spermicide partner fulfil criterion ) , abstinence screen 30 day last dose study drug 4 . Body weight ≥ 50 kg inclusive body mass index ( BMI ) range 19.0 30.0 kg/m2 , extremes include 5 . Willing abstain caffeine xanthinecontaining beverage , include coffee tea , alcohol , grapefruit juice , bitter orange study period 6 . Willing sign Informed Consent Form ( ICF ) indicate understands purpose procedure require study willing participate study 7 . Presence chronic hepatitis C ( CHC ) document : Positive antiHCV antibody least 6 month screen ; A liver biopsy Elastoscan/Fibroscan/FibroSURE perform screen evidence CHC , presence fibrosis and/or inflammation 8 . Positive antiHCV antibody screen 9 . Absence ( medical history physical finding ) ascites , bleed esophageal varix , hepatic encephalopathy , sign symptom decompensated liver disease 10 . Presence HCV RNA level ≥ 1x105 IU/mL screen 11 . Presence genotype 1b , 2a , 3a HCVinfection screen 12 . Treatmentnaïve HCVinfected subject eligible receive interferon , ribavirin , HCV protease inhibitor viable HCV treatment plan establish HCV care provider Exclusion Criteria Part B : Subjects must exclude meet follow criterion : 1 . Breastfeeding pregnant female 2 . History heart arrhythmia ( clinically relevant ) baseline prolongation QTcF interval &gt; 430 m ( male ) &gt; 450 m ( female ) , history risk factor Torsade de Pointes syndrome ( hypokalemia , family history long QT syndrome ) , HR ( supine pulse obtain vital sign ) &lt; 50 bpm &gt; 100 bpm 3 . History suspicion current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance study procedures 4 . Hepatitis A B infection ( confirm hepatitis A antibody IgM , hepatitis B surface antigen , respectively ) HIV1 HIV2 infection ( confirm CLIA test ) study screen 5 . Clinically relevant , currently active underlie gastrointestinal , cardiovascular , nervous system , psychiatric , metabolic ( e.g. , diabetes mellitus ) , renal , hepatic , respiratory , inflammatory , infectious disease 6 . History drug allergy , limited , sulfonamides penicillin , drug allergy witness previous trial investigational drug 7 . Any condition , opinion investigator , would compromise study wellbeing subject prevent subject meeting performing study requirement 8 . Use prohibit medication herbal remedy within 14 day prior first dose study drug administration 9 . Donation blood plasma 250 mL within 60 day precede study 10 . Subjects one follow laboratory abnormality screen defined Division Microbiology Infectious Diseases ( DMID ) Adult Toxicity Table : Hemoglobin grade 1 great ( ≤ 10.5 gm/dL ) Platelet count grade 1 great ( &lt; 100,000/mm3 ) Absolute neutrophil count grade 1 great ( ≤ 1500/mm3 ) AST ALT &gt; 5x ULN Total bilirubin &gt; 1.5x ULN Prothrombin time INR &gt; 1.5x ULN Lipase grade 1 great ( &gt; 1.1x ULN ) Serum creatinine grade 1 great ( &gt; 1.1x ULN ) Any laboratory abnormality ≥ grade 2 [ Note : Retesting abnormal lab value may lead exclusion allow ( without prior Sponsor approval ) . Retesting take place unscheduled visit Screening phase ( admission/baseline ) ] 11 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment psychiatric illness , history suicide attempt depression 12 . Received investigational drug within 30 day prior first dose study drug administration 13 . Coinfections HIV1 , HIV2 liver infection 14 . History evidence cirrhosis decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>MB-110</keyword>
</DOC>